Ignyta News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.06.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, RADI, FOCS (PR Newswire)
23.05.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, MDWT, RUTH (PR Newswire)
11.05.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTV, RXDX (PR Newswire)
01.05.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR (PR Newswire)
25.04.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA (PR Newswire)
17.04.23	SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates RXDX, STSA, CHRA (PR Newswire)
16.04.23	Prometheus Biosciences To Be Acquired By Merck (RTTNews)
09.12.22	Prometheus Biosciences Prices Underwritten Offering Of About 4.55 Mln Shares At $110/shr (RTTNews)
03.10.22	Prometheus Hits New High - What Next? (RTTNews)
28.12.21	12 Healthcare Stocks That Trade At Premium To Their IPO Price (RTTNews)
04.01.18	Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference (Businesswire)
29.12.17	Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor (Businesswire)
22.12.17	Ignyta Holding On To Substantial Gain In Afternoon Trading (RTTNews)
22.12.17	WeissLaw LLP Investigates Ignyta Inc. Acquisition (PR Newswire)
22.12.17	SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Ignyta, Inc. - RXDX (PR Newswire)
22.12.17	Ignyta Agrees To Be Bought By Roche In $1.7 Bln Cash Deal - Quick Facts (RTTNews)
22.12.17	Roche and Ignyta Reach Definitive Merger Agreement (Businesswire)
29.11.17	Ignyta to Participate at the Global Mizuho Investor Conference (Businesswire)
22.11.17	Ignyta to Present at the 29th Annual Piper Jaffray Healthcare Conference (Businesswire)
16.11.17	Ignyta Reports Granting of Inducement Awards (Businesswire)
09.11.17	Ignyta to Present at the Jefferies 2017 London Healthcare Conference (Businesswire)
08.11.17	Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting (Businesswire)
07.11.17	Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results (Businesswire)
01.11.17	Ignyta to Present at Credit Suisse 26th Annual Healthcare Conference (Businesswire)
19.10.17	FDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX Slumps (RTTNews)
18.09.17	Stock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health (PR Newswire)
07.09.17	Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress (Businesswire)
13.07.17	Stock Performance Review on Biotech Industry -- Athersys, AVEO Pharma, Heat Biologics, and Ignyta (PR Newswire)
16.05.17	Gainers & Losers Of May 15: CBMG, ETRM, ALNY, EGRX, ONCS... (RTTNews)
04.05.17	Gainers & Losers Of May 3: PIRS, MYGN, XENT, RXDX, SPPI... (RTTNews)
16.02.17	Gainers & Losers Of The Day: ZSAN, EVOK, ARDX, EARS, NEOT... (RTTNews)
03.02.17	Gainers & Losers Of The Day: BNTC, PULM, CALA, STML, CORI... (RTTNews)
02.12.16	Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting (Businesswire)
29.11.16	Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting (Businesswire)
22.11.16	Ignyta to Host Conference Call and Webcast at EORTC-NCI-AACR Symposium on December 1, 2016 (Businesswire)
14.11.16	Ignyta Announces Six Upcoming Presentations at the 2016 EORTC-NCI-AACR Annual Meeting (Businesswire)
10.11.16	Ignyta to Present at the Jefferies 2016 London Healthcare Conference (Businesswire)
03.11.16	Ignyta Announces Presentation at the CTOS 21st Annual Meeting in Lisbon, Portugal (Businesswire)
02.05.16	RXDX Prices Offering At $6.25/Share (RTTNews)
18.04.16	FDA Snubs CHMA, NICE Is Nice With PTCT, RXII To Effect Reverse Split (RTTNews)
08.12.15	Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma (Businesswire)
30.11.15	Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program (Businesswire)
08.11.15	Ignyta Buys Exclusive Rights To Taladegib Oncology Program From Lilly (RTTNews)
27.09.15	Ignyta Announces Updated Interim Data from Entrectinib Phase 1 Clinical Trials at the 2015 European Cancer Congress (Businesswire)
21.09.15	Ignyta Announces Entrectinib Phase 1 Data Presentation at the 2015 European Cancer Congress (Businesswire)
11.06.15	RXDX Prices Offering At $17.50/Share (RTTNews)
19.04.15	Ignyta To Make Poster Presentations At 2015 AACR Annual Meeting - Quick Facts (RTTNews)
18.03.15	Deal Ignites Ignyta, ESPR Surges On Study Results, MCUR Ahead Of Timeline (RTTNews)
17.03.15	Ignyta Announces Acquisition Of Four Oncology R&D Assets From Teva (RTTNews)
18.02.15	Eagle Soars, VBLT Crushed Over Drug Failure, Study Fails To Soothe CLTX (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.17		Roche-Übernahmeziel Ignyta erhält FDA-Freigabe für Krebs-Wirkstoff
22.12.17		Roche übernimmt US-Onkologieunternehmen Ignyta für 1,7 Mrd USD

29.12.17

Roche-Übernahmeziel Ignyta erhält FDA-Freigabe für Krebs-Wirkstoff

22.12.17

Roche übernimmt US-Onkologieunternehmen Ignyta für 1,7 Mrd USD

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Ignyta Inc

Aktien Top/Flop

Ignyta Peer Group Nachrichten

Meistgelesene Nachrichten